HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies (Review)

References

• Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001; 166: 6257–6265
   PubMed Web of Science ®Google Scholar
• Alfsen A, Bomsel M. HIV-1 gp41 envelope residues 650–685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002; 277: 25649–25659
   PubMed Web of Science ®Google Scholar
• Almeida PF, Pokorny A, Hinderliter A. Thermodynamics of membrane domains. Biochim Biophys Acta 2005; 1720: 1–13
   PubMed Web of Science ®Google Scholar
• Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci USA 1988; 85: 900–904
   PubMed Web of Science ®Google Scholar
• Aloia RC, Tian H, Jensen FC. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci USA 1993; 90: 5181–5185
   PubMed Web of Science ®Google Scholar
• Alving CR. Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans 1984; 12: 342–344
   PubMed Web of Science ®Google Scholar
• Alving CR. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986; 40: 303–314
   PubMed Web of Science ®Google Scholar
• Alving CR. 2006. Antibodies to lipids and liposomes: immunology and safety. J Liposome Res 16:157–166.
   PubMed Web of Science ®Google Scholar
• Alving CR, Richards RL. Immune reactivities of antibodies against glycolipids. II. Comparative properties, using liposomes, of purified antibodies against mono-, di- and trihexosyl ceramide haptens. Immunochemistry 1977; 14: 383–389
   PubMedGoogle Scholar
• Alving CR, Wassef NM. Naturally-occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunology Today 1999; 20: 362–366
   PubMedGoogle Scholar
• Alving CR, Swartz GM, Jr. Antibodies to cholesterol, cholesterol conjugates, and liposomes: Implications for atherosclerosis and autoimmunity. CRC Crit Rev Immunol 1991; 10: 441–453
   Google Scholar
• Alving CR, Swartz GM, Jr, Wassef NM. Naturally-occurring autoantibodies to cholesterol in humans. Biochem. Soc. Trans. 1989; 17: 637–639
   Google Scholar
• Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, Katinger HW. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16: 227–233
   PubMed Web of Science ®Google Scholar
• Armbruster C, Stiegler GM, Vcelar BA, Jager W, Koller U, Jilch R, Ammann CG, Pruenster M, Stoiber H, Katinger HW. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004; 54: 915–920
   PubMed Web of Science ®Google Scholar
• Avila JL, Rojas M, Avila A. Cholesterol sulphate-reactive autoantibodies are specifically increased in chronic chagasic human patients. Clin Exp Immunol 1996; 103: 40–46
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200–206
   PubMed Web of Science ®Google Scholar
• Bhattacharya J, Repik A, Clapham PR. Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes. J Virol 2006; 80: 5292–5300
   PubMed Web of Science ®Google Scholar
• Banerji B, Alving CR. Anti-liposome antibodies induced by lipid A. I. Influences of ceramide, glycosphingolipids, and phosphocholine on complement damage. J Immunol 1981; 126: 1080–1084
   PubMed Web of Science ®Google Scholar
• Banerji B, Lyon JA, Alving CR. Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes. Biochim Biophys Acta 1982; 689: 319–326
   PubMed Web of Science ®Google Scholar
• Banerji B, Alving CR. Antibodies to liposomal phosphatidylserine and phosphatidic acid. Biochem Cell Biol 1990; 68: 96–101
   PubMed Web of Science ®Google Scholar
• Bate CA, Kwiatkowski D. A monoclonal antibody that recognizes phosphatidylinositol inhibits induction of tumor necrosis factor alpha by different strains of Plasmodium falciparum. Infect Immun 1994; 62: 5261–5266
   PubMed Web of Science ®Google Scholar
• Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 2006; 118: 2639–2643
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657–700
   PubMed Web of Science ®Google Scholar
• Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silberberg DH. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci USA 1991; 88: 7131–7134
   PubMed Web of Science ®Google Scholar
• Bhat S, Mettus RV, Reddy EP, Ugen KE, Srikanthan V, Williams WV, Weiner DB. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206–275. AIDS Res Hum Retroviruses 1993; 9: 175–181
   PubMed Web of Science ®Google Scholar
• Bollinger CR, Teichgraber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta 2005; 1746: 284–294
   PubMed Web of Science ®Google Scholar
• Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, Desgranges C. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9: 277–287
   PubMed Web of Science ®Google Scholar
• Brügger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Kräusslich H-G. The HIV lipodome: a raft with an unusual composition. Proc Natl Acad Sci USA 2006; 103: 2641–2646
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5: 233–236
   PubMed Web of Science ®Google Scholar
• Cabiedes J, Cabral AR, Alarcon-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 1998; 28: 2108–2114
   PubMed Web of Science ®Google Scholar
• Callahan MK, Popernack PM, Tsutsui S, Truong L, Schlegel RA, Henderson AJ. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. J Immunol 2003; 170: 4840–4845
   PubMed Web of Science ®Google Scholar
• Campbell S, Fisher RJ, Towler EM, Fox S, Issaq HJ, Wolfe T, Phillips LF, Rein A. Modulation of HIV-like particle assembly in vitro by inositol phosphates. Proc Natl Acad Sci USA 2001; 98: 10875–10879
   PubMed Web of Science ®Google Scholar
• Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunological abnormalities. Am J Hematol 1982; 13: 121–129
   PubMed Web of Science ®Google Scholar
• Chernomordik L, Chanturiya AN, Suss-Toby E, Nora E, Zimmerberg J. An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol 1994; 68: 7115–7123
   PubMed Web of Science ®Google Scholar
• Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2003; 4: 309–319
   PubMed Web of Science ®Google Scholar
• Dijkstra J, Swartz GM, Jr, Raney JJ, Aniagolu J, Toro L, Nacy CA, Green SJ. Interaction of anti-cholesterol antibodies with human lipoproteins. J Immunol 1996; 157: 2006–2013
   PubMed Web of Science ®Google Scholar
• Doms RW. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000; 276: 229–237
   PubMed Web of Science ®Google Scholar
• Downes CP, Gray A, Lucocq JM. Probing phosphoinositide functions in signaling and membrane trafficking. Trends Cell Biol 2005; 15: 259–268
   PubMed Web of Science ®Google Scholar
• Falco M, Sorrenti A, Priori R, Luan FL, Pittoni V, Agresti MG, Valesini G. Anti-cardiolipin antibodies in HIV infection are true antiphospholipids not associated with antiphospholipid syndrome. Ann Ital Med Int 1993; 8: 171–174
   PubMedGoogle Scholar
• Fantini J, Cook DG, Nathanson N, Spitalnik SL, Gonzalez-Scarano F. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci USA 1993; 90: 2700–2704
   PubMed Web of Science ®Google Scholar
• Fantini J, Hammache D, Delezay O, Yahi N, Andre-Barres C, Rico-Lattes I, Lattes A. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry. J Biol Chem 1997; 272: 7245–7252
   PubMed Web of Science ®Google Scholar
• Fantini J, Hammache D, Delezay O, Pieroni G, Tamalet C, Yahi N. Sulfatide inhibits HIV-1 entry into CD4 − /CXCR4+ cells. Virology 1998; 246: 211–220
   PubMed Web of Science ®Google Scholar
• Fantini J, Garmy N, Mahfoud R, Yahi N. 2002. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Expert Rev Mol Med 20 December, http://www.expertreviews.org/02005392h.htm.
   Google Scholar
• Ferguson MA MG, Low G, Cross GA. Glycosyl-sn-1,2-dimyristylphosphatidylinositol is covalently linked to Trypanosoma brucei variant surface glycoprotein. J Biol Chem 1985; 260: 14547–14555
   PubMed Web of Science ®Google Scholar
• Fogler WE, Swartz GM, Jr, Alving CR. Antibodies to phospholipids and liposomes: binding of antibodies to cells. Biochim Biophys Acta 1987; 903: 265–272
   PubMed Web of Science ®Google Scholar
• Freed EO, Martin MA. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995; 69: 1984–1989
   PubMed Web of Science ®Google Scholar
• Fust G, Beck Z, Banhegyi D, Kocsis J, Biro A, Prohaszka Z. Antibodies against heat shock proteins and cholesterol in HIV infection. Mol Immunol 2005; 42: 79–85
   PubMed Web of Science ®Google Scholar
• Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D. Role of human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002; 76: 10356–10264
   PubMed Web of Science ®Google Scholar
• Hammache D, Yahi N, Pieroni G, Ariasi F, Tamalet C, Fantini J. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of glycolipids as potential HIV-1 fusion cofactors. Biochem Biophys Res Commun 1998a; 246: 117–122
   PubMed Web of Science ®Google Scholar
• Hammache D, Pieroni G, Yahi N, Delezay O, Koch N, Lafont H, Tamalet C, Fantini J. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem 1998b; 273: 7967–7971
   PubMed Web of Science ®Google Scholar
• Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999; 73: 5244–5248
   PubMed Web of Science ®Google Scholar
• Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 1991; 253: 320–323
   PubMed Web of Science ®Google Scholar
• Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906–1908
   PubMed Web of Science ®Google Scholar
• Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci USA 1996; 93: 3099–3104
   PubMed Web of Science ®Google Scholar
• Horvath A, Biro A. Anti-cholesterol antibodies in human sera. Autoimmun Rev 2003; 2: 272–277
   PubMed Web of Science ®Google Scholar
• Horvath A, Banhegyi D, Biro A, Ujhelyi E, Veres A, Horvath L, Prohaszka Z, Bacsi A, Tarjan V, Romics L, Horvath I, Toth FD, Fust G, Karadi I. High level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. Immunobiology 2001; 203: 756–768
   PubMed Web of Science ®Google Scholar
• Huang CC, Tang M, Zhang M-Y, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310: 1025–1028
   PubMed Web of Science ®Google Scholar
• Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, Wang JM, Puri A, Blumenthal R. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000; 74: 6377–6385
   PubMed Web of Science ®Google Scholar
• Jolly C, Sattentau QJ. Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol 2005; 79: 12088–12094
   PubMed Web of Science ®Google Scholar
• Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, Shai Y. Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study. J Biol Chem 1997; 272: 13496–13505
   PubMed Web of Science ®Google Scholar
• Li H, Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998; 139: 4991–4997
   PubMed Web of Science ®Google Scholar
• Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001; 17: 1009–1019
   PubMed Web of Science ®Google Scholar
• Mañes S, del Real G, Martínez-A C. Pathogens: raft hijackers. Nature Rev Immunol 2003; 3: 557–568
   PubMed Web of Science ®Google Scholar
• Mañes S, del Real G, Lacalle RA, Lucas P, Gómez-Moutón C, Sánchez-Palomino, Delgado R, Alcamí J, Mira E, Martínez-A C. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO rep 2000; 1: 190–196
   PubMed Web of Science ®Google Scholar
• Martin I, Defrise-Quertain F, Decroly E, Vandenbranden M, Brasseur R, Ruysschaert J-M. Orientation and structure of the NH2-terminal HIV-1 gp41 peptide in fused and aggregated liposomes. Biochim Biophys Acta 1993; 1145: 124–133
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207–210
   PubMed Web of Science ®Google Scholar
• Matuoka K, Fukami K, Nakanishi O, Kawai S, Takenawa T. Mitogenesis in response to PDGF and bombesin abolished by microinjection of antibody to PIP2. Science 1988; 239: 640–643
   PubMed Web of Science ®Google Scholar
• Matyas GR, Wassef NM, Rao M, Alving CR. Induction and detection of antibodies to squalene. J Immunol Methods 2000; 245: 1–14
   PubMed Web of Science ®Google Scholar
• Matyas GR, Rao M, Pittman PR, Burge R, Robbins IE, Wassef NM, Thivierge B, Alving CR. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J Immunol Methods 2004; 286: 47–67
   PubMed Web of Science ®Google Scholar
• McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ. Progress towards the development of a HIV-1 gp 41-directed vaccine. Current HIV Res 2004; 2: 193–204
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Hanke T. HIV vaccines 1983–2003. Nat Med 2003; 9: 874–880
   PubMed Web of Science ®Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–3124
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A., Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306
   PubMed Web of Science ®Google Scholar
• Miyazawa A, Umeda M, Horikoshi T, Yanagisawa K, Yoshioka T, Inoue K. Production and characterization of monoclonal antibodies that bind to phosphatidylinositol 4,5-bisphosphate. Mol Immunol 1988; 25: 1025–1031
   PubMed Web of Science ®Google Scholar
• Mooney JJ, Dalrymple JM, Alving CR, Russell PK. The interaction of Sindbis virus with liposomal model membranes. J Virol 1975; 15: 225–231
   PubMed Web of Science ®Google Scholar
• Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF 3rd, Burton DR, Ho DD. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69: 101–109
   PubMed Web of Science ®Google Scholar
• Nisole S, Krust B, Hovanessian A.G. Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res 2002; 276: 155–173
   PubMed Web of Science ®Google Scholar
• Nguyen DH, Hildreth JEK. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000; 74: 3264–3272
   PubMed Web of Science ®Google Scholar
• Ono A, Freed EO. Plasma mambrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98: 12925–13930
   Web of Science ®Google Scholar
• Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci USA 2004; 101: 14889–14894
   PubMed Web of Science ®Google Scholar
• Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, Tomer KB. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001; 75: 10906–10911
   PubMed Web of Science ®Google Scholar
• Pascual R, Moreno MR, Villalain J. A peptide pertaining to the loop segment of human immunodeficiency virus 41 binds and interacts with model biomembranes: implications for the fusion mechanism. J Virol 2005; 79: 5142–5152
   PubMed Web of Science ®Google Scholar
• Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest 2004; 114: 605–610
   PubMed Web of Science ®Google Scholar
• Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res 2003; 44: 655–667
   PubMed Web of Science ®Google Scholar
• Popik W, Alce T, Au W-C. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ cells. J Virol 2002; 76: 4709–4722
   PubMed Web of Science ®Google Scholar
• Puri A, Hug P, Jernigan K, Barchi J, Kim HY, Hamilton J, Wiels J, Murray GJ, Brady RO, Blumenthal R. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1998; 95: 14435–14440
   PubMed Web of Science ®Google Scholar
• Rajendran L, Simons K. Lipid rafts and membrane dynamics. J Cell Sci 2005; 118: 1099–1102
   PubMed Web of Science ®Google Scholar
• Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005; 11: 1551–1562
   PubMed Web of Science ®Google Scholar
• Rauch J, Janoff AS. Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo. Proc Natl Acad Sci USA 1990; 87: 4112–4114
   PubMed Web of Science ®Google Scholar
• Richards RL, Aronson J, Schoenbechler M, Diggs CL, Alving CR. Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits. J Immunol 1983; 130: 1390–1394
   PubMed Web of Science ®Google Scholar
• Rietveld A, Simons K. The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochim Biophys Acta 1998; 1376: 467–479
   PubMed Web of Science ®Google Scholar
• Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954–960
   PubMed Web of Science ®Google Scholar
• Sáez-Cirión A, Nir S, Lorizate M, Agirre A, Cruz A, Pérez-Gil J, Nieva JL. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002; 277: 21776–21785
   PubMed Web of Science ®Google Scholar
• Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Basanez G, Nieva JL. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett 2006; 580: 2395–2399
   PubMed Web of Science ®Google Scholar
• Schuster B, Neidig M, Alving BM, Alving CR. Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J Immunol 1979; 122: 900–905
   PubMed Web of Science ®Google Scholar
• Seddon JM. Structure of the inverted hexagonal (HII) phase and non-lamellar phase transitions of lipids. Biochim Biophys Acta 1990; 1031: 1–69
   PubMed Web of Science ®Google Scholar
• Silvestris F, Frassanito MA, Cafforio P, Potenza D, Di Loreto M, Tucci M, Grizzuti MA, Nico B, Dammacco F. Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. Blood. 1996; 87: 5185–5195
   PubMed Web of Science ®Google Scholar
• Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569–572
   PubMed Web of Science ®Google Scholar
• Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 2004; 33: 269–295
   PubMedGoogle Scholar
• Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175: 720–731
   PubMed Web of Science ®Google Scholar
• Stollar BD, McInerney T, Gavron T, Wassef NM, Swartz GM, Jr, Alving CR. Cross-reactions of nucleic acids with monoclonal antibodies to phosphatidylinositol phosphate and cholesterol. Mol Immunol 1989; 26: 73–79
   PubMed Web of Science ®Google Scholar
• Subczynski WK, Kusumi A. Dynamics of raft molecules in the cell and artificial membranes: approaches by pulse EPR spin labeling and single molecule optical microscopy. Biochim Biophys Acta 2003; 1610: 231–243
   PubMed Web of Science ®Google Scholar
• Swartz GM, Jr, Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving CR. Antibodies to cholesterol. Proc Natl Acad Sci USA 1988; 85: 1902–1906
   PubMed Web of Science ®Google Scholar
• Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 615–622
   PubMed Web of Science ®Google Scholar
• Trommeshauser D, Krol S, Bergelson LD, Galla HJ. The effect of lipid composition and physical state of phospholipid monolayer on the binding and incorporation of a basic amphipathic peptide from the C-terminal region of the HIV envelope protein gp41. Chem Phys Lipids 2000; 107: 83–92
   PubMed Web of Science ®Google Scholar
• Umeda M, Igarashi K, Nam KS, Inoue K. Effective production of monoclonal antibodies against phosphatidylserine: stereo-specific recognition of phosphatidylserine by monoclonal antibody. J Immunol 1989; 143: 2273–2279
   PubMed Web of Science ®Google Scholar
• Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopath 1986; 41: 8–15
   PubMedGoogle Scholar
• Vincent N, Genin C, Malvoisin E. Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta 2002; 1567: 157–164
   PubMed Web of Science ®Google Scholar
• Wassef NM, Roerdink F, Swartz GM, Jr, Lyon JA, Berson BJ, Alving CR. Phosphate binding specificities of monoclonal antibodies against phosphoinositides in liposomes. Mol Immunol 1984; 21: 863–868
   PubMed Web of Science ®Google Scholar
• Wassef NM, Swartz GM, Jr, Alving CR, Kates M. Antibodies to liposomal phosphatidylcholine and phosphatidylsulfocholine. Biochem Cell Biol 1990; 68: 54–58
   PubMed Web of Science ®Google Scholar
• Waugh MG, Lawson D, Tan SK, Hsuan JJ. Phosphatidylinositol 4-phosphate synthesis in immunoisolated caveolae-like vesicles and low buoyant density non-caveolar membranes. J Biol Chem 1998; 273: 17115–17121
   PubMed Web of Science ®Google Scholar
• Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884–1888
   PubMed Web of Science ®Google Scholar
• Yu X, Yuan X, Matsuda Z, Lee T-H, Essex M. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992; 66: 5966–4971
   Web of Science ®Google Scholar
• Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75: 10892–10905
   PubMed Web of Science ®Google Scholar